<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999752</url>
  </required_header>
  <id_info>
    <org_study_id>AVR-2009-02 (BYS-MD-27)</org_study_id>
    <nct_id>NCT00999752</nct_id>
  </id_info>
  <brief_title>Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension</brief_title>
  <acronym>NASAA</acronym>
  <official_title>A 25 Week, Open Label Study to Determine the Effects of Nebivolol When Added to Hydrochlorothiazide on Diastolic Function and Arterial Stiffness in African Americans With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InVasc Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InVasc Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the effects of Nebivolol and
      Hydrochlorothiazide on blood pressure in African Americans with high blood pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many blood pressure medications are not effective in African American men and women. The two
      lower chambers of the heart contract to pump blood to the body. The lower chambers have to
      relax so they can refill with blood to pump out again. Many patients with high blood pressure
      have stiffness in the lower chambers which prevents the heart from relaxing so it can
      properly fill with blood. Some patients with the stiffness in the lower chambers of the heart
      will develop heart failure.

      The study is to test whether or not Nebivolol (Bystolic)and a diuretic Hydrochlorothiazide
      (HCTZ) will help the heart relax so the heart can properly fill and prevent stiffness of the
      lower heart chambers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in systolic and diastolic blood pressure after treatment with nebivolol and reaching normal blood pressure &lt;140/90</measure>
    <time_frame>Every visit for 25 weeks (9 study visits)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences after nebivolol treatment on diastolic function as measured by tissue doppler imaging (ECHO), arterial compliance and stiffness and vascular nitric oxide availability determined by neutrophil function</measure>
    <time_frame>At the begining and end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nebivolol to reach blood pressure control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrochlorothiazide for blood pressure control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>5mg/day with increase to 10 mg/day to reach blood pressure &lt;140/90</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Bystolic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Hydrochlorothiazide 25 mg/day</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>HCTZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known Hypertension by history

          -  Self-described African American

        Exclusion Criteria:

          -  Uncontrolled Diabetes Mellitus (HbA1C&gt;10)

          -  Known CAD, Cerebrovascular Disease, PVD or Renovascular Disease

          -  Liver disease

          -  Chronic Renal Disease

          -  Uncontrolled Hypertension (&gt;199 systolic and/or &gt;115)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bobby V Khan, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>InVasc Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atlanta Vascular Research Foundation</name>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <zip>30084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2009</study_first_submitted>
  <study_first_submitted_qc>October 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2009</study_first_posted>
  <last_update_submitted>May 4, 2011</last_update_submitted>
  <last_update_submitted_qc>May 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Bobby V. Khan, MD PhD</name_title>
    <organization>InVasc Therapeutics, Inc.</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>African Americans</keyword>
  <keyword>Arterial Stiffness</keyword>
  <keyword>Vascular Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

